Lanthanide-controlled protein switches: development and in vitro and in vivo applications.

Lanthanides, which are part of the rare earth elements group have numerous applications in electronics, medicine and energy storage.  However, our ability to extract them is not meeting the rapidly increasing demand. The discovery of the bacterial periplasmic lanthanide-binding protein lanmodulin spurred significant interest in developing biotechnological routes for lanthanide detection and extraction.

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.

Methods: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 10 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.

Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.

Gender integration of agricultural innovation: implications for the genetically modified crop product development pipeline.

We provide guidance on how to incorporate best practices around gender integration in the development of genetically improved crops by adapting a gender integration framework for conventional crop breeding to the GM product development pipeline, which places greater emphasis on the discovery and launch phases because the technical nature of the development process means fewer opportunities for farmer engagement or pivoting possibilities between these two ends of the product development spectrum. For crop innovation to be relevant to both women and men producers, during the discovery phase, developers can conduct baseline gender analysis consisting of gender-disaggregated value chain analysis, systematic learning about gender-specific crop trait preferences, and identification of varietal preferences by women and men along the value chain. The latter opportunity in the GM product development pathway for intentional gender integration is deployment, including pre-launch activities such as field demonstrations and consumer testing.

pH-Driven Enzymatic Breakdown and Release of Catalase from Alginate Hydrogel.

Stimuli-induced release resulting in biochemical transformations has received a lot of attention due to its application in controlled drug release. In this work, catalase (EC 1.11.